• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

VIS Quiz Question #2

Poll

2. The NCVIA mandates that VIS sheets be given to persons receiving covered vaccines in which of the following groups?

A. All children under the age of 18 years
B. All persons receiving state or federal supplied vaccines, including vaccines not covered by the NCVIA
C. A and B
D. All persons receiving a covered vaccine
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Related Content
Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation

Atopic Dermatitis: Investigational Anti-OX40L Antibody Shows Sustained Itch Relief, Even After Discontinuation

Sydney Jennings
March 8th 2025
Article

AAD 2025: In a post hoc analysis of the STREAM-AD Phase 2b study, 63% of patients with AD maintained itch reduction even after stopping amlitelimab use.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis

Tapinarof Cream 1% Demonstrates Sustained Disease Control in Adults, Children with Atopic Dermatitis

Sydney Jennings
March 8th 2025
Article

AAD 2025: New analysis of the ADORING 3 trial showed tapinarof maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

Sydney Jennings
October 25th 2023
Podcast

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis

Ruxolitinib Cream Demonstrates Long-Term Disease Control in Atopic Dermatitis

Grace Halsey
March 7th 2025
Article

By the end of the TRuE-AD1 and TRuE-AD 2 studies, 30.0% of participants met all 4 disease control criteria.

Real-World Evidence Reveals Key Insights on Hidradenitis Suppurativa

Real-World Evidence Reveals Key Insights on Hidradenitis Suppurativa

Patient Care Editorial Staff
March 7th 2025
Article

Two posters at AAD 2025 highlighted different challenges of managing patients with HS.

© 2025 MJH Life Sciences

All rights reserved.